Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

Methods for Reducing Contrast Use and Avoiding Acute Kidney Injury During Endovascular Procedures

Author(s): Chrysovalantis Vergadis*, ">Georgios Festas, Eleni Spathi, Paris Pappas and ">Stavros Spiliopoulos

Volume 25 , Issue 44 , 2019

Page: [4648 - 4655] Pages: 8

DOI: 10.2174/1381612825666191211112800

Price: $65


Iodinated Contrast Media (CM) has a plethora of applications in routine non-invasive or percutaneous invasive imaging examinations and therapeutic interventions. Unfortunately, the use of CM is not without complications, with contrast-induced acute kidney injury (CI-AKI) being among the most severe.

CI-AKI is a syndrome defined as a rapid development of renal impairment after a few days of CM endovascular injection, without the presence of any other underlying related pathologies. Although mostly transient and reversible, for a subgroup of patients with comorbidities related to renal failure, CI-AKI is directly leading to longer hospitalization, elevated rates of morbidity and mortality, as well as the increased cost of funding.

Thus, a need for classification in accordance with clinical and peri-procedural criteria is emerged. This would be very useful for CI-AKI patients in order to predict the ones who would have the greatest advantage from the application of preventive strategies.

This article provides a practical review of the recent evidence concerning CI-AKI incidence, diagnosis, and sheds light on prevention methods for reducing contrast use and avoiding AKI during endovascular procedures.

In conclusion, despite the lack of a specific treatment protocol, cautious screening, assessment, identification of the high-risk patients, and thus the application of simple interventions -concerning modifiable risk factors- can significantly reduce CI-AKI risk.

Keywords: Contrast-induced acute kidney injury, prevention, risk score, chronic kidney disease, iodinated contrast media, high-risk patients.

Berlyne N, Berlyne GM. Acute renal failure following intravenous pyelography with hypaque. Acta Med Scand 1962; 171: 39-41.
[] [PMID: 13867962]
Morabito S, Pistolesi V, Benedetti G, et al. Incidence of contrast-induced acute kidney injury associated with diagnostic or interventional coronary angiography. J Nephrol 2012; 25(6): 1098-107.
[] [PMID: 22383347]
Caixeta A, Nikolsky E, Mehran R. Prevention and treatment of contrast-associated nephropathy in interventional cardiology. Curr Cardiol Rep 2009; 11(5): 377-83.
[] [PMID: 19709498]
Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006; (100): S11-5.
[] [PMID: 16612394]
Gupta RK, Bang TJ. Prevention of contrast-induced nephropathy (CIN) in interventional radiology practice. Semin Intervent Radiol 2010; 27(4): 348-59.
[] [PMID: 22550376]
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8(4): R204-12.
[] [PMID: 15312219]
Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2005; 67(6): 2089-100.
[] [PMID: 15882252]
Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11(2): R31.
[] [PMID: 17331245]
American College of Radiology. Committee on Drugs and Contrast Media ACR Manual on Contrast Media, v103. American College of Radiology 2017.
Newhouse JH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol 2008; 191(2): 376-82.
[] [PMID: 18647905]
Thomas ME, Blaine C, Dawnay A, et al. The definition of acute kidney injury and its use in practice. Kidney Int 2015; 87(1): 62-73.
[] [PMID: 25317932]
Fliser D, Laville M, Covic A, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant 2012; 27(12): 4263-72.
[] [PMID: 23045432]
Tumlin J, Stacul F, Adam A, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006; 98(6A): 14K-20K.
[] [PMID: 16949376]
Sendeski M, Patzak A, Pallone TL, Cao C, Persson AE, Persson PB. Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy. Radiology 2009; 251(3): 697-704.
[] [PMID: 19366904]
Wong PC, Li Z, Guo J, Zhang A. Pathophysiology of contrast-induced nephropathy. Int J Cardiol 2012; 158(2): 186-92.
[] [PMID: 21784541]
Heinrich MC, Kuhlmann MK, Grgic A, Heckmann M, Kramann B, Uder M. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology 2005; 235(3): 843-9.
[] [PMID: 15845795]
Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005; 68(1): 14-22.
[] [PMID: 15954892]
Seeliger E, Lenhard DC, Persson PB. Contrast media viscosity versus osmolality in kidney injury: lessons from animal studies. BioMed Res Int 2014; 2014358136
Hardiek K, Katholi RE, Ramkumar V, Deitrick C. Proximal tubule cell response to radiographic contrast media. Am J Physiol Renal Physiol 2001; 280(1): F61-70.
[] [PMID: 11133515]
Ueda J, Nygren A, Hansell P, Ulfendahl HR. Effect of intravenous contrast media on proximal and distal tubular hydrostatic pressure in the rat kidney. Acta Radiol 1993; 34(1): 83-7.
[] [PMID: 8427755]
Brown JR, DeVries JT, Piper WD, et al. Serious renal dysfunction after percutaneous coronary interventions can be predicted. Am Heart J 2008; 155(2): 260-6.
[] [PMID: 18215595]
McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006; 98(6A): 27K-36K.
[] [PMID: 16949378]
Stevens MA, McCullough PA, Tobin KJ, et al. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. J Am Coll Cardiol 1999; 33(2): 403-11.
[] [PMID: 9973020]
Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004; 94(3): 300-5.
[] [PMID: 15276092]
Pakfetrat M, Nikoo MH, Malekmakan L, et al. Comparison of risk factors for contrast-induced acute kidney injury between patients with and without diabetes. Hemodial Int 2010; 14(4): 387-92.
[] [PMID: 20796046]
Qian G, Fu Z, Guo J, Cao F, Chen Y. Prevention of contrast-induced nephropathy by central venous pressure-guided fluid administration in chronic kidney disease and congestive heart failure patients. JACC Cardiovasc Interv 2016; 9(1): 89-96.
[] [PMID: 26685074]
Sidhu RB, Brown JR, Robb JF, et al. Interaction of gender and age on post cardiac catheterization contrast-induced acute kidney injury. Am J Cardiol 2008; 102(11): 1482-6.
[] [PMID: 19026300]
Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44(7): 1393-9.
[] [PMID: 15464318]
Murakami R, Kumita S, Hayashi H, et al. Anemia and the risk of contrast-induced nephropathy in patients with renal insufficiency undergoing contrast-enhanced MDCT. Eur J Radiol 2013; 82(10): e521-4.
[] [PMID: 23827802]
Peng F, Su J, Lin J, Niu W. Impact of renin-angiotensin-aldosterone system-blocking agents on the risk of contrast-induced acute kidney injury: a prospective study and meta-analysis. J Cardiovasc Pharmacol 2015; 65(3): 262-8.
[] [PMID: 25502308]
Cirit M, Toprak O, Yesil M, et al. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract 2006; 104(1): c20-7.
[] [PMID: 16685140]
Peer A, Averbukh Z, Berman S, Modai D, Averbukh M, Weissgarten J. Contrast media augmented apoptosis of cultured renal mesangial, tubular, epithelial, endothelial, and hepatic cells. Invest Radiol 2003; 38(3): 177-82.
[] [PMID: 12595799]
Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54(23): 2205-41.
[] [PMID: 19942100]
Anne G, Gruberg L, Huber A, et al. Traditional versus automated injection contrast system in diagnostic and percutaneous coronary interventional procedures: comparison of the contrast volume delivered. J Invasive Cardiol 2004; 16(7): 360-2.
[PMID: 15282428]
Osprey Medical, Inc AVERT Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN (AVERT) 2015 Available at.
Gurm HS, Dixon SR, Smith DE, et al. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2011; 58(9): 907-14.
[] [PMID: 21851878]
Katzberg RW, Barrett BJ. Risk of iodinated contrast material--induced nephropathy with intravenous administration. Radiology 2007; 243(3): 622-8.
[] [PMID: 17446526]
Ellis JH, Cohan RH. Reducing the risk of contrast-induced nephropathy: a perspective on the controversies. AJR Am J Roentgenol 2009; 192(6): 1544-9.
[] [PMID: 19457817]
Sharafuddin MJ, Marjan AE. Current status of carbon dioxide angiography. J Vasc Surg 2017; 66(2): 618-37.
[] [PMID: 28735955]
Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003; 93(1): C29-34.
[] [PMID: 12411756]
Nikolsky E, Mehran R. Hydration protocols to reduce the incidence of contrast-induced nephropathy. J Invasive Cardiol 2008; 20(10): 527-38.
[PMID: 18829997]
Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124(23): e574-651.
[] [PMID: 22070834]
McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51(15): 1419-28.
[] [PMID: 18402894]
ontrast Media Safety Committee ESUR Guidelines on contrast agents version 10th; CMSC 2018 Available at.
Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162(3): 329-36.
[] [PMID: 11822926]
Zapata-Chica CA, Bello Marquez D, Serna-Higuita LM, Nieto-Ríos JF, Casas-Arroyave FD, Donado-Gómez JH. Sodium bicarbonate versus isotonic saline solution to prevent contrast-induced nephropathy: a systematic review and meta-analysis. Colomb Med 2015; 46(3): 90-103.
[] [PMID: 26600623]
Brar SS, Hiremath S, Dangas G, Mehran R, Brar SK, Leon MB. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4(10): 1584-92.
[] [PMID: 19713291]
Brar SS, Aharonian V, Mansukhani P, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet 2014; 383(9931): 1814-23.
[] [PMID: 24856027]
Mehran R, Caixeta A. N-acetylcysteine in preventing contrast-induced nephropathy. To give, or not to give: that is the question. Rev Esp Cardiol 2010; 63(1): 9-11.
[] [PMID: 20089220]
Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol 2008; 3(1): 281-7.
[] [PMID: 18003766]
Shlipak MG, Matsushita K, Ärnlöv J, et al. CKD Prognosis Consortium. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013; 369(10): 932-43.
[] [PMID: 24004120]
Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2(1): 1-138.
Rodrigues GJ, Lunardi CN, Lima RG, et al. Vitamin C improves the effect of a new nitric oxide donor on the vascular smooth muscle from renal hypertensive rats. Nitric Oxide 2008; 18(3): 176-83.
[] [PMID: 18194676]
McCullough PA, Akrawinthawong K. Ascorbic acid for the prevention of contrast-induced acute kidney injury. J Am Coll Cardiol 2013; 62(23): 2176-7.
[] [PMID: 23994411]
Sadat U, Usman A, Gillard JH, Boyle JR. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials. J Am Coll Cardiol 2013; 62(23): 2167-75.
[] [PMID: 23994417]
Singh N, Lee JZ, Huang JJ, et al. Benefit of statin pretreatment in prevention of contrast-induced nephropathy in different adult patient population: systematic review and meta-analysis. Open Heart 2014; 1(1) e000127
[] [PMID: 25332824]
Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One 2012; 7(4) e34450
[] [PMID: 22511942]
Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol 2014; 63(1): 71-9.
[] [PMID: 24076283]
Marenzi G, Cosentino N, Werba JP, Tedesco CC, Veglia F, Bartorelli AL. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. Int J Cardiol 2015; 183: 47-53.
Grenader A, Healy DP. Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells. J Pharmacol Exp Ther 1991; 258(1): 193-8.
[PMID: 1677038]
US Food and Drugs administration (FDA) Available at. Approved Drug Products.History [accessed November 14, 2011]
Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002; 143(5): 894-903.
[] [PMID: 12040355]
Landoni G, Biondi-Zoccai GG, Tumlin JA, et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis 2007; 49(1): 56-68.
[] [PMID: 17185146]
Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopammesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290(17): 2284-91.
[] [PMID: 14600187]
Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002; 57(3): 279-83.
[] [PMID: 12410497]
Dai B, Liu Y, Fu L, Li Y, Zhang J, Mei C. Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2012; 60(3): 360-70.
[] [PMID: 22516682]
Song K, Jiang S, Shi Y, Shen H, Shi X, Jing D. Renal replacement therapy for prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Nephrol 2010; 32(5): 497-504.
[] [PMID: 20975263]
Tasanarong A, Vohakiat A, Hutayanon P, Piyayotai D. New strategy of α- and γ-tocopherol to prevent contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures. Nephrol Dial Transplant 2013; 28(2): 337-44.
[] [PMID: 23314316]
Russo D, Testa A, Della Volpe L, Sansone G. Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron 1990; 55(3): 254-7.
[] [PMID: 2370924]
Neumayer HH, Junge W, Küfner A, Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant 1989; 4(12): 1030-6.
[PMID: 2517323]
Carraro M, Mancini W, Artero M, et al. Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Nephrol Dial Transplant 1996; 11(3): 444-8.
[] [PMID: 8671813]
Khoury Z, Schlicht JR, Como J, et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy 1995; 15(1): 59-65.
[PMID: 7739947]
Diamantopoulos A, Kyriazis I, Geronatsiou K, et al. Parstatin prevents renal injury following ischemia/reperfusion and radiocontrast administration. Am J Nephrol 2012; 36(3): 278-86.
[] [PMID: 22965158]
Uchino S, Doig GS, Bellomo R, et al. Diuretics and mortality in acute renal failure. Crit Care Med 2004; 32(8): 1669-77.
[] [PMID: 15286542]
Kokko JP. Site and mechanism of action of diuretics. Am J Med 1984; 77(5A): 11-7.
[] [PMID: 6496555]
Cantarovich F, Fernandez JC, Locatelli A, Perez Loredo J. Frusemide in high doses in the treatment of acute renal failure. Postgrad Med J 1971; 47(Suppl.): 13-7.
[PMID: 5579763]
Kleinknecht D, Ganeval D, Gonzalez-Duque LA, Fermanian J. Furosemide in acute oliguric renal failure. A controlled trial. Nephron 1976; 17(1): 51-8.
[] [PMID: 778649]
Karayannopoulos S. Letter: high-dose frusemide in renal failure. BMJ 1974; 2(5913): 278-9.
[PMID: 4827098]
Putzu A, Boscolo Berto M, Belletti A, et al. Prevention of contrast-induced acute kidney injury by furosemide with matched hydration in patients undergoing interventional procedures: a systematic review and meta-analysis of randomized trials. JACC Cardiovasc Interv 2017; 10(4): 355-63.
[] [PMID: 28231903]
Dorval J-F, Dixon SR, Zelman RB, Davidson CJ, Rudko R, Resnic FS. Feasibility study of the RenalGuard™ balanced hydration system: a novel strategy for the prevention of contrast-induced nephropathy in high risk patients. Int J Cardiol 2013; 166(2): 482-6.
[] [PMID: 22204847]
Bagshaw SM, Delaney A, Jones D, Ronco C, Bellomo R. Diuretics in the Management of Acute Kidney Injury: A Multinational Survey. Contrib Nephrol 2007; 156: 236-49.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy